If people on Medicare are hospitalized for COVID-19 related illness, how much can they expect to have to pay for the hospital stay? We analyzed potential out-of-pocket expenses for those in traditional Medicare and Medicare Advantage.
This analysis examines the share of Part D enrollees who currently have access to extended supplies of generic, brand-name, and specialty-tier drugs covered by their plan in 2020, prior to relaxation of any early-fill restrictions in response to the COVID-19 outbreak. Early-fill restritictions could prevent enrollees from obtaining a sufficient extended supply to meet their needs.
Virtually all Medicare beneficiaries are at greater risk of becoming seriously ill if they are infected with the new coronavirus that causes COVID-19. Diagnosis is confirmed through testing, and treatment varies based on the severity of illness. We review current policies for Medicare coverage and costs associated with testing and treatment for COVID-19.
Congress is considering legislation this week to lower prescription drug costs. Our chartpack summarizes key provisions in three House and Senate bills and their likely impact on prices, people and federal spending.
A relatively small share of people with Medicare Advantage or stand-alone Medicare Part D prescription drug coverage voluntarily switch plans during Medicare’s open enrollment period from Oct. 15 to Dec. 7.